Contineum Therapeutics (CTNM) Free Cash Flow (2023 - 2026)

Contineum Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$11.5 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 26.73% year-over-year to -$11.5 million; the TTM figure through Jun 2026 stood at -$53.5 million (down 14.89% YoY), while the FY2025 annual figure was -$55.5 million, down 74.07% from the prior year.
• Free Cash Flow for Q2 2026 stood at -$11.5 million, up from -$16.6 million in the prior quarter.
• The five-year high for Free Cash Flow was $40.6 million in Q2 2023, with the low at -$16.6 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$10.6 million (2023), against an average of -$6.9 million.
• The sharpest annual moves came in 2024 and 2026: Free Cash Flow sank 118.25% in 2024, then increased 26.73% in 2026.
• Contineum Therapeutics' Free Cash Flow stood at -$11.0 million in 2023, then climbed by 7.36% to -$10.2 million in 2024, then retreated by 28.25% to -$13.1 million in 2025, then increased by 12.05% to -$11.5 million in 2026.
• Business Quant data shows CTNM's Free Cash Flow at -$11.5 million in Q2 2026, -$16.6 million in Q1 2026, and -$13.1 million in Q4 2025.